Quotables
"Everyone acquainted with the subject will recognize it as a conspicuous failure."
Henry Morton, president of the Stevens Institute of Technology ; Said in 1880 about the light bulb
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8119388 | Non-tumorigenic MDCK cell line for propagating viruses The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically,... | 02/21/2012 |
| 7901920 | Virosome-like-particles The invention relates to the production of virosome-like-particles. The invention provides a method for producing a virosome-like-particle comprising contacting an enveloped virus with a solution containing a short-chain phospholipid allowing solubilisation of the v... | 03/08/2011 |
| 7883884 | Concept for slurry separation and biogas production The present invention concerns an anaerobic digestion of animal manures, energy crops and similar organic substrates. The process is capable of refining nutrients comprised in the digested biomass to fertilizers of commercial quality. The invention also provides a m... | 02/08/2011 |
| 7741099 | Adenoviral vectors and uses thereof The present invention relates to recombinant adenoviral vectors based on adenoviruses that encounter pre-existing immunity in a minority of the human population and which harbor a chimeric capsid. The chimeric capsid comprises fiber proteins that have at least the k... | 06/22/2010 |
| 7727757 | Methods of eliciting antiviral immune responses utilizing viral particles comprising photoinactivated reverse transcriptase Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke an immune r... | 06/01/2010 |
| 7556957 | Coronavirus-like particles comprising functionally deleted genomes The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) de... | 07/07/2009 |
| 7494799 | Paramunity inducers based on attenuated rabbit myxoma virus The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and ... | 02/24/2009 |
| 7465574 | Recombinant RSV virus expression systems and vaccines The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to ... | 12/16/2008 |
| 7439058 | HBV/HCV virus-like particle Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an im... | 10/21/2008 |
| 7419816 | Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS A mutant virus contains a mutation at a phosphorylation site in one or more viral proteins, which attenuates the virus, and an improved vaccine composition. The invention also relates to methods of inducing an immune response, and protecting mammals from infection b... | 09/02/2008 |
| 7413889 | Production of a parvovirus vaccine in plants as viral coat protein fusions The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusio... | 08/19/2008 |
| 7393527 | Method for limiting the growth of cancer cells using an attenuated measles virus A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 10... | 07/01/2008 |
| 7384643 | Recombinant poxvirus Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the CXC group. ... | 06/10/2008 |
| 7378265 | Method of inactivating enveloped viruses in a viral preparation of non-enveloped viruses The present invention relates to a method of inactivating enveloped viruses in a viral preparation predominantly containing non-enveloped viruses by the action of a solvent at a temperature of between −5° C. and +50° C. and at a pH of between about 5 and 9. Its ... | 05/27/2008 |
| 7374768 | Viral vaccines A mutant virus for use as a vaccine for prophylaxis or therapy, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus, e.g. a herpesvirus, e.g HSV-1 or HSV-2, is capable of ... | 05/20/2008 |
| 7364729 | Method of inducing a CTL response Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL ... | 04/29/2008 |
| 7351527 | Immunizing fish against viral infection The present invention provides the isolated causative agent of the disease affecting Cyprinus carpino and a method for its isolation. The invention further provides avirulent forms, e.g., live-attenuated form, inactivated form and genetically modified forms o... | 04/01/2008 |
| 7348138 | Method of inducing cell death using West Nile virus capsid protein This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from... | 03/25/2008 |
| 7344723 | Self-replicating RNA molecule from hepatitis C virus A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV... | 03/18/2008 |
| 7341731 | HIV-2 antigen compositions The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immun... | 03/11/2008 |
| 7335364 | Modified Vaccinia Ankara virus variant The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus... | 02/26/2008 |
| 7332322 | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof The present invention provides a Venezuelan equine encephalitis virus replicon RNA useful in the development of stable lines of mammalian, avian and insect cells in which these replicons will persistently replicate. Venezuelan equine encephalitis (VEE) virus replico... | 02/19/2008 |
| 7312064 | DNA transfection system for the generation of infectious influenza virus The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably ... | 12/25/2007 |
| 7309493 | Inactivated bovine scours vaccines, process and method of preventing bovine scours Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inacti... | 12/18/2007 |
| 7291723 | GB virus C and methods of treating viral infections The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences. ... | 11/06/2007 |
| 7291342 | Infectious bronchitis virus vaccine Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus... | 11/06/2007 |
| 7285381 | Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof. | 10/23/2007 |
| 7276333 | Viral infection inhibitor targeting integrase N-terminal domain The object of the present invention is to provide a screening method of a new integrase inhibitor being able to inhibit an HIV infection before the reverse transcription step and having a pharmaceutical site of action totally different from those of traditional inte... | 10/02/2007 |
| 7252984 | Attenuated mutant newcastle disease virus strains for in ovo vaccination, method for preparing and their use The present invention relates to new attenuated mutant New Castle's disease La SotaNewcastle disease virus strains suitable for in ovo vaccination of avian species comprising a mutation in the gene sequences encoding the HN and/or F glycoproteins of said virus. Furt... | 08/07/2007 |
| 7244558 | Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an ope... | 07/17/2007 |
| 7244434 | Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be ... | 07/17/2007 |
| 7238672 | Chimeric lyssavirus nucleic acids and polypeptides The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the im... | 07/03/2007 |
| 7235391 | Formulation of adenovirus for gene therapy The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired ... | 06/26/2007 |
| 7235235 | Alphavirus RNA replicon systems The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) ... | 06/26/2007 |
| 7229625 | Retrovirus-like particles made non-infectious by a plurality of mutations Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H ac... | 06/12/2007 |
| 7223584 | Recombinant rabies vaccine and methods of preparation and use Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of anti-rabies immunity in a subject. ... | 05/29/2007 |
| 7214524 | Marek's disease virus vaccine An effective vaccine for Marek's disease may be prepared using a viral agent which is a Marek's disease virus unable to express a functional meq protein. This viral agent is effective to elicit an immune response in a chicken to very virulent strains of Marek's dise... | 05/08/2007 |
| 7211378 | Filovirus vectors and noninfectious filovirus-based particles Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles. ... | 05/01/2007 |
| 7211260 | Infectious bursitis vaccine The present invention is concerned with isolated infectious bursitis (or bursal) disease virus(es) and a vaccine containing said virus(es) which is capable of protecting poultry against disease caused by infectious bursitis virus, characterized in that the vaccine v... | 05/01/2007 |
| 7205013 | Recombinant RSV virus expression systems and vaccines The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant ... | 04/17/2007 |
